Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.46 |
| ▸ | IL1B | P01584 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | CASP3 | P42574 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247762 | 1.00 | CASP1 (0.46) | CASP1IL1BACEACE2TACR1 | |
| SCHEMBL10248117 | 0.89 | CASP1 (0.46) | CASP1IL1BCASP3 | |
| SCHEMBL10199551 | 0.89 | CASP1 (0.46) | CASP1IL1BCASP3 | |
| SCHEMBL10247686 | 0.89 | CASP1 (0.45) | CASP1IL1BCASP3 | |
| SCHEMBL10199269 | 0.89 | CASP1 (0.45) | CASP1IL1BCASP3 | |
| SCHEMBL10199578 | 0.87 | CASP1 (0.44) | CASP1IL1BACETACR1CASP3 | |
| SCHEMBL646760 | 0.86 | CASP1 (0.64) | CASP1IL1BACE | |
| SCHEMBL10199457 | 0.86 | CASP1 (0.64) | CASP1IL1BACE | |
| SCHEMBL10199840 | 0.82 | CASP1 (0.46) | CASP1IL1BACECASP3 | |
| SCHEMBL10247775 | 0.82 | CASP1 (0.46) | CASP1IL1BACECASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP1 6/4885IL1B 3/4885ACE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.